Inhibikase Therapeutics (IKT)
(Real Time Quote from BATS)
$1.36 USD
-0.11 (-7.48%)
Updated May 1, 2024 02:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Cash flow Statements
Fiscal Year End for Inhibikase Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -19.03 | -18.05 | -14.79 | -2.85 | -5.72 |
Depreciation/Amortization & Depletion | 0.18 | 0.01 | 0.00 | 0.00 | 0.00 |
Net Change from Assets/Liabilities | 0.23 | 0.17 | -1.76 | -0.46 | 1.63 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 0.53 | 0.53 | 2.25 | 2.18 | 3.75 |
Net Cash From Operating Activities | -18.09 | -17.35 | -14.30 | -1.13 | -0.34 |
Property & Equipment | -0.01 | -0.24 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 11.67 | -15.76 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 11.66 | -16.01 | 0.00 | 0.00 | 0.00 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 8.54 | 0.04 | 41.21 | 0.00 | 0.00 |
Issuance (Repayment) of Debt | 0.00 | -0.25 | -0.04 | 0.27 | -0.02 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.14 | 0.00 | -0.08 | 14.79 | 0.00 |
Net Cash from Financing Activities | 8.41 | -0.20 | 41.09 | 15.06 | -0.02 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 1.98 | -33.56 | 26.80 | 13.94 | -0.36 |
Cash at Beginning of Period | 7.19 | 40.75 | 13.95 | 0.02 | 0.38 |
Cash at End of Period | 9.17 | 7.19 | 40.75 | 13.95 | 0.02 |
Diluted Net EPS | -3.57 | -4.32 | -4.86 | -2.10 | -4.20 |
Fiscal Year End for Inhibikase Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -19.03 | -14.85 | -10.26 | -4.48 |
Depreciation/Amortization & Depletion | NA | 0.18 | 0.17 | 0.16 | 0.01 |
Net Change from Assets/Liabilities | NA | 0.23 | -0.36 | -0.69 | -1.62 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 0.53 | 0.40 | 0.25 | 0.12 |
Net Cash From Operating Activities | NA | -18.09 | -14.64 | -10.54 | -5.97 |
Property & Equipment | NA | -0.01 | -0.01 | -0.01 | 0.00 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 11.67 | 13.79 | -3.27 | -5.84 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 11.66 | 13.77 | -3.29 | -5.84 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 8.54 | 8.54 | 8.54 | 8.58 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -0.14 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 8.41 | 8.54 | 8.54 | 8.58 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | 1.98 | 7.67 | -5.28 | -3.23 |
Cash at Beginning of Period | NA | 7.19 | 7.19 | 7.19 | 7.19 |
Cash at End of Period | NA | 9.17 | 14.86 | 1.91 | 3.96 |
Diluted Net EPS | NA | -0.64 | -0.86 | -1.11 | -0.96 |